Tiago Cunha Reis’ Post

Exploring extracellular vesicles as a drug delivery system for cancer therapy: in this review article, Jiabing Lian at China Medical University and collaborators offered a comprehensive overview of extracellular vesicles, detailing their biogenesis and absorption mechanisms. Additionally, they explored current research efforts aimed at utilizing EVs as drug carriers, covering purification techniques, drug loading, and bioengineering for targeted delivery https://lnkd.in/eTCm_t4Z Their analysis highlighted the potential of EVs as versatile and effective tools for drug delivery, especially in cancer therapy. An article co-authored by Jin Wang and Bohang Yin #extracellularvesicles #exosomes #drugdelivery #cancertherapy #bioengineering #Vesiculab

ACTIVE loading of vesicles with drugs results in an intra-vesicular drug concentration significantly higher than in the loading medium. For example, the remote loading of liposomes with doxorubicin via an ammonium gradient (the prototype of ACTIVE loading) yields liposomes with drug concentrations inside the liposomes >100-fold the drug level in the loading medium. I severely doubt any of the "active drug loading" methods listed in this paper are able to achieve that. Baring a special interaction of the drug with lipid membranes or components already inside EVs, the intra-vesicular drug concentration can never be higher than in the loading medium, neither by electroporation, sonication, detergent treatment, extrusion nor by freeze-thawing cycles. All these 5 methods lack a driving force leading to an ACCUMULUATION of the drug inside the vesicle. The term "active loading" is wrongly used in this paper. I am happy to be challenged on my opinion, I am open for any discussion and if I am wrong, I would be happy to stand corrected.

Exploring the molecular intricacy of CD19: a key player in immunotherapy! 🧬 Delving into the structure of the B-lymphocyte antigen CD19 with its distinctive domains and antibody binding sites. This molecular understanding is paving the way for groundbreaking advancements in targeted cancer treatments. #Immunotherapy #CD19 #CancerResearch #MolecularBiology #Biotech #Science #HealthcareInnovation #CART #shenclinicalservices

Calling all #biopharma researchers! Looking for new cancer drug candidates? Need trusted genomic data to validate targets? Compiling data for clinical trial design?? Look no further! COSMIC and HSMD are here to supercharge your research efforts. These expert-curated somatic databases are your keys to unlocking fast, cost-effective, and precise cancer #drugdiscovery and development. Special offer: Click here to learn more, get a free trial, plus free sample data https://buff.ly/3Vqw6Z4 QIAGEN Digital Insights

Are you interested in having a quick overview of approved targeted therapies and #CDx assays for non-small cell lung cancer (NSCLC) patients? If the answer is yes, keep reading! Did you know that there are: - 62 CDx approvals (all methodologies included) - based on 16 assays (out of which 4 are tissue- and 2 liquid biopsy NGS-based assays) and - they are manufactured by 9 providers only! On a leading position is #Roche (including Foundation Medicine) which holds 37 CDx approvals, followed by #LifeTechnologies (8 CDx's), #Qiagen (6), #GuardantHealth (4), #Agilent (Dako) (3), #Abbott (2), #PillarBiosciences (1) and #ExactSciences (Resolution Biosciences (1)).  This goes along with 24 molecularly matched therapies, of which, 3 are combo therapies. I also provide you with the list of new approvals/extensions that have occurred during Q1 2024. Let me know if this is useful (and shout if anything is missing!) ! Have a great Friday everyone! #molecularlymatchedtherapies #targetedtherapies #precisiononcology #CDx

Excellent overview of ADC target selection from Pythia Bio!

Stay informed, stay ahead in the fight against cancer! From organic to inorganic and hybrid types, discover how nanocarriers are revolutionizing drug delivery to tumor sites, enhancing therapeutic outcomes in cancer treatment. Read more here from the University of Puerto Rico about the latest advancements and clinical developments in nanocarrier technology: https://ow.ly/9qvO50R7FsS #Nanomedicine #CancerResearch #DrugDelivery

Did you know? Combining checkpoint inhibitors with myeloid-targeted therapies may unlock new possibilities for cancer patients. #ImmunoOncology #CancerResearch #CheckpointInhibitors #BioTech #InnovativeMedicine #HealthcareInnovation #MedicalScience #Research #TargetedTherapy

Human PBMC-derived killer cells are incubated with various target cancer cells, representing solid and hematologic malignancies. Target cell death can be measured using rapid and cost-effective methods, including flow cytometry, IFNg secretion, luminescence, and Calcein-Acetyoxymethyl release. interested in learning more about our capabilities? contact us to schedule a meeting ==> pharmaseed@pharmaseedltd.com visit our website ==> https://lnkd.in/d-zS3V26 #cro #preclinical #preclinicalresearch #invitro #immunotherapy #immunooncology

Stay informed, stay ahead in the fight against cancer! From organic to inorganic and hybrid types, discover how nanocarriers are revolutionizing drug delivery to tumor sites, enhancing therapeutic outcomes in cancer treatment. Read more here from the University of Puerto Rico about the latest advancements and clinical developments in nanocarrier technology: https://ow.ly/e53650R7FsP #Nanomedicine #CancerResearch #DrugDelivery